References
- Carrabba MG, Reni M, Foppoli M, . Treatment approaches for primary CNS lymphomas. J Expert Opin Pharmacother 2010;11:1263–1276.
- Reni M, Ferreri AJ, Garancini MP, . Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997;8:227–234.
- Ferreri AJ, Reni M, Foppoli M, . High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512–1520.
- Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, . Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003;70:219–224.
- Enting RH, Demapoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901–903.
- Reni M, Mason W, Zaja F, . Salvage chemotherapy with temozolamide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004;40:1682–1688.
- Fischer L, Thiel E, Klasen HA, . Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006;17: 1141–1145.
- De Rossi A, Rossi L, Laudisi A, . Focus on fotemustine. J Exp Clin Cancer Res 2006;25:461–468.
- Musso M, Scalone R, Marcacci G, . Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010;45:1147–1153.